Transition Bio

Transition Bio is a drug discovery company headquartered in Watertown, Massachusetts, that is building a platform around condensate science — the study of biomolecular condensates, the membrane-less compartments inside cells that organize biochemistry in space and time. The company describes itself as combining the technology and data engine of Harvard's Weitz Lab and the University of Cambridge's Knowles Lab to create what it calls the only end-to-end condensate drug discovery platform built on molecular insights. The scientific foundation of Transition Bio rests on the work of its scientific co-founders, David A. Weitz of Harvard University and Tuomas Knowles of the University of Cambridge. Weitz is a soft-matter physicist and biophysicist whose laboratory developed widely adopted techniques for probing biomaterials, while Knowles is a physical chemist and biophysicist who has studied protein aggregation, protein self-assembly, and protein-protein interactions, and co-directs the Cambridge Centre for Misfolding Diseases. Their combined expertise in physics, chemistry, biology, and machine learning underpins the company's approach to some of the most fundamental challenges in health and disease. At the technical level, Transition Bio's platform unites droplet microfluidics with state-of-the-art cellular imaging. This combination allows the company to reveal how chemical matter affects condensate systems at the molecular level, generating data that is then used to optimize drug candidates through machine learning and artificial intelligence. The company positions this engine as a way to tackle targets and biology that have historically been difficult to drug. Transition Bio has disclosed a lead small-molecule inhibitor program targeting YTHDC1, which it presented at the AACR-NCI-EORTC 2025 conference. The program showed robust efficacy in MYC-driven cancers, both as a single agent and in combination with standard-of-care therapies. The company has also entered a drug discovery collaboration with Voyager Therapeutics targeting TDP-43 for ALS and FTD, and announced a partnership with the Little Warrior Foundation, a childhood cancer non-profit focused on Ewing Sarcoma. These activities indicate an active pipeline and partnership strategy spanning oncology and neuroscience. As a private company, Transition Bio does not disclose financial results publicly. Its operations span the United States and the United Kingdom, reflecting the transatlantic academic roots of its founding science. The company continues to develop its condensate drug discovery platform and to pursue collaborations that apply it to high-unmet-need diseases.

Transition Bio was founded to translate advances in condensate science into new medicines. The company's scientific co-founders, David A. Weitz of Harvard University and Tuomas Knowles of the University of Cambridge, brought together expertise in soft-matter physics, biophysics, protein aggregation, and protein self-assembly. Their laboratories developed widely adopted techniques for investigating biomaterials and protein interactions, and the company was created to integrate these advances with machine learning and artificial intelligence for drug discovery. The company is headquartered in Watertown, Massachusetts, and maintains a transatlantic presence reflecting its academic roots in the United States and the United Kingdom. It describes its platform as the only end-to-end condensate drug discovery platform built on molecular insights, combining droplet microfluidics and state-of-the-art cellular imaging to reveal the impact of chemical matter on condensate systems at the molecular level. Transition Bio has advanced a lead small-molecule inhibitor program targeting YTHDC1, presenting results at AACR-NCI-EORTC 2025 that highlighted robust efficacy in MYC-driven cancers as a single agent and in combination with standard-of-care therapies. The company has also pursued external collaborations, including a drug discovery collaboration with Voyager Therapeutics targeting TDP-43 for ALS and FTD, and a partnership with the Little Warrior Foundation focused on Ewing Sarcoma. These activities reflect a strategy of applying its condensate platform across oncology and neuroscience while partnering to expand its reach into additional disease areas.

• Presented results of lead YTHDC1 small-molecule inhibitor program at AACR-NCI-EORTC 2025.

• Entered drug discovery collaboration with Voyager Therapeutics targeting TDP-43 for ALS and FTD.

• Announced partnership with the Little Warrior Foundation for Ewing Sarcoma research.

A drug discovery company applying condensate science, droplet microfluidics, cellular imaging, and machine learning to discover medicines for difficult targets.

• End-to-end condensate drug discovery platform

  Integrates droplet microfluidics, cellular imaging, and machine learning to reveal the impact of chemical matter on condensate systems at the molecular level.

• YTHDC1 small-molecule inhibitor program

  Lead program targeting YTHDC1, showing efficacy in MYC-driven cancers as a single agent and in combination with standard-of-care therapies.

1. 1Transition Bio – Cutting Edge Condensate Sciencetransitionbio.com
2. 2About Us – Transition Biotransitionbio.com
3. 3Transition Biowikidata.org